HBOT for Spinal Cord Injury | NorCal Hyperbarics Concord, CA

Spinal cord injury (SCI) is a catastrophic neurological event that disrupts the communication pathways between the brain and the body below the injury level, producing varying degrees of paralysis, sensory loss, autonomic dysfunction, and loss of bladder, bowel, and sexual function. In the United States, approximately 300,000 people are currently living with SCI, with 17,000 to 18,000 new injuries occurring each year. Motor vehicle accidents are the leading cause (38%), followed by falls (31%), violence (13%), and sports and recreation activities (8%). The Bay Area's significant military and veteran population at Travis Air Force Base and Mather adds another demographic with elevated SCI risk from combat and training injuries.

SCI is classified by the American Spinal Injury Association (ASIA) Impairment Scale from A (complete: no motor or sensory function below injury level) to E (normal function). Incomplete injuries — those with partial preservation of motor or sensory function — have substantially greater rehabilitation potential and are particularly important candidates for aggressive adjunctive therapy including HBOT, where even partial functional recovery represents life-changing outcomes.

The injury levels correspond to functional consequences: cervical injuries (C1-C8) cause quadriplegia affecting all four limbs and often respiratory function; thoracic injuries (T1-T12) produce paraplegia with preservation of arm function; lumbar injuries affect leg function with varying degrees of bowel and bladder involvement.

The concept of the secondary injury cascade is central to understanding both the pathophysiology of SCI and HBOT's role in its treatment. The primary injury — the mechanical disruption of spinal cord tissue at the moment of impact — is irreversible and untreatable. But the secondary injury that follows — ischemia, edema, free radical production, inflammatory mediator release, and excitotoxicity that expands the zone of damage over hours to days — represents a potentially modifiable target. HBOT's window for maximum neuroprotective benefit is in the acute phase: within the first 24 to 48 hours when this secondary cascade is most active.

In the acute phase, HBOT at 2.0 to 2.5 atmospheres delivers oxygen to the ischemic penumbra surrounding the primary lesion, reduces edema by downregulating vascular permeability mediators, suppresses the microglial activation and cytokine storm driving progressive neuronal death, and reduces free radical-mediated lipid peroxidation in neural membranes. Animal studies of acute SCI consistently demonstrate reduced lesion size and better motor recovery with early HBOT compared to controls. In the chronic phase, HBOT promotes neuroplasticity through BDNF upregulation, angiogenesis in hypoxic peri-injury tissue, and stem cell mobilization — supporting partial recovery in incomplete injuries even years after the original event.

For the chronic SCI complications that significantly affect quality of life — particularly pressure ulcers — HBOT addresses the wound healing failure directly by restoring oxygen to the ischemic insensate skin and stimulating the angiogenesis needed for wound bed preparation. Pressure ulcers in SCI patients are often deep (Stage III or IV), chronically infected, and highly resistant to standard wound care. HBOT, coordinated with surgical debridement and infection management, provides the oxygen environment needed for wound closure. Dr. Toth coordinates with rehabilitation medicine and wound care teams throughout the Bay Area to provide integrated SCI management.